An audit of the management of malignant hypercalcaemia.
A protocol was designed to help junior doctors to manage patients with malignant hypercalcaemia (MH). Seventy-five patients received 30 mg, 60 mg or 90 mg doses of pamidronate, depending on their initial serum calcium level. Fifty-four (72%) patients achieved normocalcaemia (NC) within 5 days after a single infusion of pamidronate. A further ten (13%) patients reached NC after a second dose, and 11 (15%) remained hypercalcaemic until death. NC was maintained for a median duration of 24 days. Patients received, on average, 30 mg less pamidronate than that given in the manufacturer's dosing schedule. The protocol was considered effective, economical and practical in the routine management of MH.
Gerrard
G E
GE
Yorkshire Regional Centre for Cancer Treatment, Cookridge Hospital, Leeds, UK.
Dodwell
D J
DJ
Vail
A
A
Watters
J
J
Overend
M A
MA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002118:Calcium / Q000097:blood; D002985:Clinical Protocols; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007262:Infusions, Intravenous; D008297:Male; D008485:Medical Audit; D008505:Medical Staff, Hospital; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D000077268:Pamidronate
D004164:Diphosphonates; D000077268:Pamidronate; D002118:Calcium